Expression of the microtubule-associated protein 2 (MAP2) as a potential independent prognostic marker in prostate cancer
CONCLUSION: The present data support MAP2 as a novel biomarker in PCA specimens. MAP2 is correlated with tumor grade and MAP2 high-expressing PCA is associated with an increased risk of biochemical recurrence after radical prostatectomy. Future studies are necessary to evaluate MAP2 as a valuable immunohistochemical biomarker in preoperative PCA diagnostic procedures, in particular with regard to treatment modalities.PMID:38310601 | PMC:PMC10838842 | DOI:10.1007/s00432-023-05579-0 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 4, 2024 Category: Cancer & Oncology Authors: Johannes Stein Eliana Krappe Anika Kremer Marcus V Cronauer Markus Essler Alexander Cox Niklas Kl ümper Philipp Krausewitz J örg Ellinger Manuel Ritter Glen Kristiansen Michael Majores Source Type: research
Sporadic Prostate Cancer in a Patient With Lynch Syndrome
Mayo Clin Proc. 2024 Feb;99(2):344-345. doi: 10.1016/j.mayocp.2023.11.001.NO ABSTRACTPMID:38309942 | DOI:10.1016/j.mayocp.2023.11.001 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 3, 2024 Category: Cancer & Oncology Authors: Ameya Patil Lori A Erickson Sounak Gupta Source Type: research
Determination of enzalutamide long-term safety and efficacy for castration-resistant prostate cancer patients after combined anti-androgen blockade followed by alternative anti-androgen therapy: a multicenter prospective DELC study
CONCLUSIONS: In the DELC study, the safety of enzalutamide was comparable to that in previous reports. Serum levels of neuron-specific enolase and interleukin-6 were suggested as prognostic factors for castration-resistant prostate cancer with potential clinical utility.PMID:38305451 | DOI:10.1093/jjco/hyae004 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Akira Nagahara Motohide Uemura Mototaka Sato Wataru Nakata Masao Tsujihata Tetsuya Takao Soichi Matsumura Kensaku Nishimura Shingo Takada Toshichika Iwanishi Yasuyuki Kobayashi Yu Ishizuya Tsuyoshi Takada Koichi Okada Hitoshi Inoue Taigo Kato Koji Hatano Source Type: research
Real-world data on the comprehensive genetic profiling test for Japanese patients with metastatic castration-resistant prostate cancer
CONCLUSIONS: the results of this study showed the promising survival outcomes in patients with genotype-matched therapy under public insurance, even in the castration-resistant prostate cancer setting. Further detection of promising therapeutic target gene is expected to increase the number of patients who reach genotype-matched therapies.PMID:38305663 | DOI:10.1093/jjco/hyae003 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Dai Koguchi Hideyasu Tsumura Ken-Ichi Tabata Soichiro Shimura Takefumi Satoh Masaomi Ikeda Akinori Watanabe Tsutomu Yoshida Jiichiro Sasaki Kazumasa Matsumoto Masatsugu Iwamura Source Type: research
Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression
CONCLUSION: Upregulation of SRC-1 indicates a higher risk of progression to metastatic disease in a shorter period, which warrants further research to be applied as a clinical tool. Additionally, AR may be used as a predictor for PCa recurrence. Furthermore, AR-V7 may be helpful as a diagnostic tool for PCa and locally advanced cancer, comparable with other investigated tools.PMID:38305916 | PMC:PMC10837222 | DOI:10.1007/s00432-023-05598-x (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Ruan Pimenta Feres Camargo Malulf Poliana Rom ão Giovana Vilas Boas Caetano Karina Serafim da Silva Vitoria Ghazarian Gabriel A Dos Santos Vanessa Guimar ães Iran Amorim Silva Juliana Alves de Camargo Saulo Recuero B árbara V Lima Aguiar Melão Alberto Source Type: research
ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature
CONCLUSIONS: In diverse CSPC patient populations, ERBB3 OE was associated with high AR signaling despite low intraprostatic androgen. Mechanistic studies demonstrated a direct link between HER3 and enzalutamide resistance. ERBB3 OE as a biomarker could thus stratify patients for intensification of therapy in castration-sensitive disease, including targeting HER3 directly to improve sensitivity to AR-targeted therapies.PMID:38306015 | DOI:10.1158/1078-0432.CCR-23-2161 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Jordan E Vellky Brenna J Kirkpatrick Lisa C Gutgesell Mathias Morales Ryan M Brown Yaqi Wu Mark Maienschein-Cline Lucia D Notardonato Michael S Weinfeld Ryan H Nguyen Eileen Brister Maria Sverdlov Li Liu Ziqiao Xu Steven Kregel Larisa Nonn Donald J Vander Source Type: research
Quadruplet Therapy in De Novo High-Volume Mixed Neuroendocrine Prostate Cancer Using 177Lu-PSMA: A Case Report
We present a case of de novo high-volume metastatic prostate cancer with high PSMA expression, partially PSMA-negative, using quadruplet therapy (PROMISE ver. 2 miTNM; miT4N2M1aM1b(dmi) PRIMARY score: 5, PSMA-expression score: 0-3). Because of our patient's partial PSMA negativity and after a multidisciplinary tumor board discussion, we decided to use a modified protocol involving doublet hormonal therapy along with 177Lu-PSMA and radiation therapy to address the PSMA-negative disease. The patient responded well to this treatment, but recurrence was ultimately inevitable. This case represents a typical example of mixed neu...
Source: Clinical Prostate Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Emran Askari Kamran Aryana Amir Hosein Jafarian Alireza Bari Somaye Barashki Source Type: research
The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients
CONCLUSIONS: The current study indicates no OCM-disadvantage in ST + CN ccmRCC patients, relative to their ST alone counterparts. Conversely, a strong association with lower CSM was recorded in ST + CN patients, relative to their ST alone counterparts. These associations are robust and remained unchanged after strictest statistical adjustment including control for immortal time bias.PMID:38307818 | DOI:10.1016/j.clgc.2023.12.013 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 2, 2024 Category: Cancer & Oncology Authors: Reha-Baris Incesu Francesco Barletta Cristina Cano Garcia Lukas Scheipner Simone Morra Andrea Baudo Anis Assad Zhe Tian Fred Saad Shahrokh F Shariat Luca Carmignani Nicola Longo Sascha Ahyai Felix K H Chun Alberto Briganti Derya Tilki Markus Graefen Pierr Source Type: research
A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer
CONCLUSIONS: Acapatamab was safe and tolerated and had a manageable CRS profile. Preliminary signs of efficacy with limited durable antitumor activity were observed. Acapatamab demonstrated pharmacokinetic and pharmacodynamic activity.PMID:38300720 | DOI:10.1158/1078-0432.CCR-23-2978 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 1, 2024 Category: Cancer & Oncology Authors: Tanya Dorff Lisa G Horvath Karen Autio Alice Bernard-Tessier Matthew B Rettig Jean-Pascal Machiels Mehmet A Bilen Martijn P Lolkema Nabil Adra Sylvie Rottey Richard Greil Nobuaki Matsubara Daniel S W Tan Alvin Wong Hiroji Uemura Charlotte Lemech Johannes Source Type: research
Early change in apparent diffusion coefficient as a predictor of response to neoadjuvant androgen deprivation and external beam radiation therapy for intermediate- to high-risk prostate cancer
CONCLUSION: This pilot study demonstrates the potential for early ADC metrics as a biomarker of response to nADT and EBRT in intermediate to high-risk PCA.PMID:38302377 | DOI:10.1016/j.crad.2023.12.022 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 1, 2024 Category: Cancer & Oncology Authors: F B Franco J E Leeman A Fedorov M Vangel F M Fennessy Source Type: research
Quantified treatment effect at the individual level is more indicative for personalized radical prostatectomy recommendation: implications for prostate cancer treatment using deep learning
CONCLUSIONS: Our highly interpretable and reliable DL model (SNB) may identify patients with PCa who could benefit from RP, outperforming other models and clinical guidelines. Additionally, the DL-based treatment guidelines obtained can provide priori evidence for subsequent studies.PMID:38302801 | PMC:PMC10834597 | DOI:10.1007/s00432-023-05602-4 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - February 1, 2024 Category: Cancer & Oncology Authors: Huiqing Pan Jiayi Wang Weizhong Shi Ziqin Xu Enzhao Zhu Source Type: research
An unusual presentation of metastatic prostate cancer in a 44-year-old man: A case report and review of the literature
Clin Case Rep. 2024 Jan 28;12(2):e8447. doi: 10.1002/ccr3.8447. eCollection 2024 Feb.ABSTRACTProstate cancer is one of the two most common non-cutaneous cancers in men. Its presentation might be with unusual symptoms and cause the wrong initial diagnosis. This case report discusses a rare neurologic manifestation of advanced metastatic cancer in a low-risk man. He had been receiving treatment for multiple sclerosis incorrectly due to unusual manifestations such as claudication and pelvic, leg, and shoulder pain. The patient underwent a whole-body bone scan and then a transrectal ultrasound-guided biopsy, which confirmed me...
Source: Clinical Prostate Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Homa Taheri Pouya Ebrahimi Pedram Nazari Amirhosein Kefayat Abbas Mahdavian Source Type: research
Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts
CONCLUSION: MKI67 expression was positively associated with the Gleason Score, T stage, and N stage and showed a strong diagnostic and prognostic ability in PCa.PMID:38292624 | PMC:PMC10824173 | DOI:10.12998/wjcc.v12.i1.32 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Zhen Song Qi Zhou Jiang-Lei Zhang Jun Ouyang Zhi-Yu Zhang Source Type: research
Radiotherapy for hyoid bone metastasis from lung adenocarcinoma: A case report
CONCLUSION: Palliative radiotherapy may add to the quality of life in symptomatic patients with cancer metastatic to the hyoid bone.PMID:38292655 | PMC:PMC10823947 | DOI:10.5306/wjco.v15.i1.159 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Jonathan Hsu Kambridge Hribar Joseph Poen Source Type: research
Inflammatory response in gastrointestinal cancers: Overview of six transmembrane epithelial antigens of the prostate in pathophysiology and clinical implications
World J Clin Oncol. 2024 Jan 24;15(1):9-22. doi: 10.5306/wjco.v15.i1.9.ABSTRACTChronic inflammation is known to increase the risk of gastrointestinal cancers (GICs), the common solid tumors worldwide. Precancerous lesions, such as chronic atrophic inflammation and ulcers, are related to inflammatory responses in vivo and likely to occur in hyperplasia and tumorigenesis. Unfortunately, due to the lack of effective therapeutic targets, the prognosis of patients with GICs is still unsatisfactory. Interestingly, it is found that six transmembrane epithelial antigens of the prostate (STEAPs), a group of metal reductases, are si...
Source: Clinical Prostate Cancer - January 31, 2024 Category: Cancer & Oncology Authors: Ze-Xuan Fang Wen-Jia Chen Zheng Wu Yan-Yu Hou Yang-Zheng Lan Hua-Tao Wu Jing Liu Source Type: research
